Join
Live feed
·
PRReleasevia Quantisnow
Cel-Sci Corporation logo

Leading Oncology Journal Accepts For Publication New CEL-SCI Multikine Phase 3 Data Demonstrating Overall Survival Benefit in Underserved Head and Neck Cancer Patients

ByQuantisnow·Wall Street's wire, on your screen.
CVM· Cel-Sci Corporation
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track CVM (Cel-Sci Corporation) and more on Quantisnow.